An FDA approval could be worth over $100 billion to this biotech stock

Biogen may have come up with a way to treat Alzheimer's — they can't stop it, but they might be able to slow it down. The analysts were all skeptical. Now, one by one, they're starting to come around.
Wed, Oct 30 20197:33 PM EST